Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

Launched by HACKENSACK MERIDIAN HEALTH · Dec 12, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring whether a medication called Tamsulosin can help reduce the occurrence of urinary retention after surgery in older men who are having surgery for lung or chest cancer. Urinary retention means that a person has trouble emptying their bladder, which can be uncomfortable and may require additional treatment. The study aims to see if Tamsulosin can help these men regain their normal urinary function after the surgery.

To participate in this trial, men must be at least 55 years old and scheduled for a specific type of thoracic surgery related to cancer. However, certain factors would exclude someone from joining, such as already taking Tamsulosin, having low blood pressure, or having a history of certain heart conditions. Participants in this study can expect to take Tamsulosin and then be monitored for how quickly they return to normal urinary function after their surgery. The trial is currently looking for volunteers to take part.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Males
• • ≥55 years old
• • Planned thoracic oncological surgical procedure of a video assisted oncological surgical procedure for suspected or confirmed cancer.
• • Surgery scheduled more than 7 days from the time of consent
• Exclusion Criteria:
• • Using Tamsulosin already
• • Known allergy to Tamsulosin or sulfa drugs
• • Current use of Boceprevir
• • Resting systolic blood pressure \<100
• • Orthostatic hypotension of \>20mm Hg systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent
• • Known history of hypotension
• • Known diagnosis of congestive heart failure (CHF) and valvular heart disease
• • History of prior prostate surgery (prostatectomy, trans-urethral resection)